Levacetylleucine

CHEMBL56021 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
173.2 g/mol
LogP
0.5
Phase
4

This modified amino acid derivative has been investigated for the treatment of rare inherited neurological conditions called neuronal ceroid lipofuscinoses (Batten disease), where it may help stabilize cell membranes and reduce neurodegeneration. Research into its therapeutic potential for these devastating childhood diseases is ongoing.

น้ำหนักโมเลกุล

173.2100 g/mol

LogP

0.50

TPSA

66.40 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@@H](CC(C)C)C(=O)O

InChI

InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1

Molecular Formula

C8H15NO3

HBD / HBA

2 / 3

พันธะที่หมุนได้

4

อะตอมหนัก

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This modified amino acid derivative has been investigated for the treatment of rare inherited neurological conditions called neuronal ceroid lipofuscinoses (Batten disease), where it may help stabilize cell membranes and reduce neurodegeneration. Research into its therapeutic potential for these devastating childhood diseases is ongoing.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Levacetylleucine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL56021. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 70912. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.